Recent Updates
Recently added Catalysts

MK0916

Phase 2

Diabetes Mellitus, Type 2 | Small molecule | Metabolic |Merck & Company, Inc.|Last Updated: May 22, 2015

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLEDBiomarker
Total Trials1
Total Enrollment154
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00543595MK0916 in Patients With Type 2 Diabetes and Metabolic Syndrome (0916-005)PHASE2 COMPLETED 154Aug 1, 2004May 1, 2005May 22, 2015 -
Unlock Drug Trial Details
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Interventions
NameTypeDescription
MK0916DRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 65 Years
SexALL
Healthy VolunteersNo

Inclusion Criteria: * Have Type 2 Diabetes * 18 to 65 years of age Exclusion Criteria: * History of Type 1 Diabetes Mellitus * Have been treated with insulin in the past 8 weeks * On a weight loss program and have ongoing weight loss * Taking weight loss medication * Have had surgery requiring ge...

Unlock Eligibility Criteria